title: Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
authors.affiliation: Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Allison
authors.forename: K
authors.initials: K
authors.lastname: Seino
authors.forename: H
authors.initials: H
authors.lastname: Yagita
mesh_terms: D000818:Animals; D053222:Fas Ligand Protein; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D051379:Mice; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation / Q000276:immunology / Q000473:pathology; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000378:metabolism*
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins